Drug Approval | September 29, 2024
Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
The net-zero target approval complements the company's near-term emission reduction targets
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Developed in consultation with clinicians and patients for an enhanced user experience
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Potential of Ayurveda’s contribution in global health system through various innovative practices
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Subscribe To Our Newsletter & Stay Updated
